Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies

TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in